



Appendix B. Ongoing and Settled BPCIA Cases From 2025

Case Name	Court	Filing Date	Biosimilar at Issue	Reference Product at Issue	# Asserted Patents ¹	Status
<i>Regeneron v. Mylan, Biocon</i> (1:22-cv-00061)	N.D.W. Va.	8/2/2022	Yesafili™	Eylea®	24	Settled.
<i>Regeneron v. Celltrion</i> (1:23-cv-00089)	N.D.W. Va.	11/8/2023	Eydenzelt®	Eylea®	38	Settled.
<i>Regeneron v. Samsung Bioepis</i> (1:23-cv-00094)	N.D.W. Va.	11/21/2023	Opuviz™	Eylea®	37	Settled.
<i>Regeneron v. Formycon</i> (1:23-cv-00097)	N.D.W. Va.	11/29/2023	Ahzantive®	Eylea®	39	Settled.
<i>Regeneron v. Samsung Bioepis</i> (1:23-cv-00106)	N.D.W. Va.	12/27/2023	Opuviz™	Eylea®	51	Settled.
<i>Regeneron v. Amgen</i> (1:24-cv-00039)	C.D. Cal./ N.D.W. Va. ²	1/10/2024	Pavblu™	Eylea®	32	Pending.
<i>Regeneron v. Celltrion</i> (1:24-cv-00053)	N.D.W. Va.	5/17/2024	Eydenzelt®	Eylea®	25	Settled.

¹ Patents asserted in the original complaints.

² This case was originally filed in the Central District of California with case number 2:24-cv-00264. In April 2024, the case was transferred to the Northern District of West Virginia and assigned case number 1:24-cv-00039.

Case Name	Court	Filing Date	Biosimilar at Issue	Reference Product at Issue	# Asserted Patents ¹	Status
<i>Regeneron v. Sandoz</i> (1:24-cv-00085)	D.N.J./ N.D.W. Va. ³	8/26/2024	Enzeevu™	Eylea®	46	Settled.
<i>Regeneron v. Amgen</i> (1:25-cv-00074)	C.D. Cal./ N.D.W. Va. ⁴	6/17/2025	Pavblu™	Eylea®	1	Pending.
<i>Biogen v. Sandoz</i> (1:22-cv-01190)	D. Del.	9/9/2022	Tyruko®	Tysabri®	28	Pending.
<i>Amgen v. Samsung Bioepis</i> (1:24-cv-08417)	D.N.J.	8/12/2024	Ospomyv™ and Xbryk™	Prolia® and Xgeva®	34	Settled.
<i>Amgen v. Fresenius Kabi</i> (1:24-cv-09555)	N.D. Ill.	10/4/2024	Bomynta® and Conexence®	Prolia® and Xgeva®	33	Settled.
<i>Amgen v. Accord</i> (5:24-cv-00642)	E.D.N.C.	11/13/2024	Osvyrti® and Jubereq®	Prolia® and Xgeva®	34	Settled.
<i>Amgen v. Sandoz</i> (1:23-cv-02406)	D.N.J.	5/1/2023	Jubbonti® and Wyost®	Prolia® and Xgeva®	21	Settled.
<i>Amgen v. Celltrion</i> (1:24-cv-06497)	D.N.J.	5/28/2024	Osenvelt® and Stoboclo®	Prolia® and Xgeva®	29	Settled.
<i>Amgen v. Biocon,</i> (1:25-cv-13358)	D. Mass./ D.N.J. ⁵	6/30/2025	Bosaya™ and Aukelso™	Prolia® and Xgeva®	34	Settled.

³ This case was originally filed in the District of New Jersey with case number 2:24-cv-08760. In September 2024, the case was transferred to the Northern District of West Virginia and assigned case number 1:24-cv-00085.

⁴ This case was originally filed in the Central District of California with case number 2:25-cv-05499. In July 2025, the case was transferred to the Northern District of West Virginia and assigned case number 1:25-cv-00074.

⁵ This case was originally filed in the District of Massachusetts with case number 1:25-cv-11867. In July 2025, the case was transferred to the District of New Jersey and assigned case number 1:25-cv-13358.

Case Name	Court	Filing Date	Biosimilar at Issue	Reference Product at Issue	# Asserted Patents ¹	Status
<i>Amgen v. Hikma</i> (1:25-cv-12152)	D.N.J.	6/25/2025	Enoby™ and Xtrenbo™	Prolia® and Xgeva®	32	Settled.
<i>Amgen v. Shanghai Henlius</i> (1:25-cv-12160)	D.N.J.	6/25/2025	Bildyos® and Bilprevda®	Prolia® and Xgeva®	26	Pending.
<i>Amgen v. Dr. Reddy's Labs.,</i> (1:25-cv-17277)	D.N.J.	11/6/2025	AVT03	Prolia® and Xgeva®	31	Pending.
<i>Amgen v. Amneal</i> (1:25-cv-17278)	D.N.J.	11/6/2025	Boncresta™ and Oziltus™	Prolia® and Xgeva®	31	Pending.
<i>Amgen v. Alkem</i> (1:25-cv-17596)	D.N.J.	11/14/2025	ENZ215	Prolia® and Xgeva®	33	Pending.
<i>Genentech v. Shanghai Henlius</i> (2:25-cv-14684)	D.N.J.	8/14/2025	Poherdy®	Perjeta®	24	Settled.